Clinical characteristics of veterans prescribed high doses of opioid medications for chronic non-cancer pain

Mental Health and Clinical Neurosciences Division, Portland VA Medical Center, Department of Psychiatry, Oregon Health & Science University, Portland, OR 97239, USA.
Pain (Impact Factor: 5.84). 12/2010; 151(3):625-32. DOI: 10.1016/j.pain.2010.08.002
Source: PubMed

ABSTRACT Little is known about patients prescribed high doses of opioids to treat chronic non-cancer pain, though these patients may be at higher risk for medication-related complications. We describe the prevalence of high-dose opioid use and associated demographic and clinical characteristics among veterans treated in a VA regional healthcare network. Veterans with chronic non-cancer pain prescribed high doses of opioids (≥ 180 mg/day morphine equivalent; n=478) for 90+ consecutive days were compared to two groups with chronic pain: Traditional-dose (5-179 mg/day; n=500) or no opioid (n=500). High-dose opioid use occurred in 2.4% of all chronic pain patients and in 8.2% of all chronic pain patients prescribed opioids long-term. The average dose in the high-dose group was 324.9 (SD=285.1)mg/day. The only significant demographic difference among groups was race (p=0.03) with black veterans less likely to receive high doses. High-dose patients were more likely to have four or more pain diagnoses and the highest rates of medical, psychiatric, and substance use disorders. After controlling for demographic factors and VA facility, neuropathy, low back pain, and nicotine dependence diagnoses were associated with increased likelihood of high-dose prescriptions. High-dose patients frequently did not receive care consistent with treatment guidelines: there was frequent use of short-acting opioids, urine drug screens were administered to only 25.7% of patients in the prior year, and 32.0% received concurrent benzodiazepine prescriptions, which may increase risk for overdose and death. Further study is needed to identify better predictors of high-dose usage, as well as the efficacy and safety of such dosing.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Limited research examines the risk of therapeutic opioid addiction (TOA) in patients with chronic non-cancer pain. This study examined TOA among 199 patients undergoing chronic opioid therapy at the time of admission to a pain rehabilitation program. It was hypothesized that non-opioid substance use disorders and opioid dosage would predict TOA. Daily mean opioid dose was 132.85mg ±175.39. Patients with non-opioid substance use disorders had 28x the odds (OR = 28.58; 95% CI = 10.86, 75.27) of having TOA. Each 50mg increase in opioid dose nearly doubled the odds of TOA (OR = 1.73; 95% CI = 1.29, 2.32). A 100mg increase was associated with a three-fold increase in odds (OR = 3.00; 95% CI =1.67, 5.41). Receiver operating characteristic analysis revealed that opioid dose was a moderately accurate predictor (AUC = .75; 95% CI = .68, .82) of TOA. The sensitivity (.70) and specificity (.68) of opioid dose in predicting TOA was maximized at 76.10mg; 46.00mg yielded 80% sensitivity in identifying TOA. These results underscore the importance of obtaining a substance use history prior to prescribing and suggest a low screening threshold for TOA in patients who use opioids in the absence of improvement in pain or functional impairment. This article examines TOA in patients with chronic non-cancer pain undergoing chronic opioid therapy. Results suggest that patients should be screened for non-opioid substance use disorders prior to prescribing. In the absence of improvement in pain or function, there is a low threshold (∼50mg daily opioid dose) for addiction screening. Copyright © 2014 American Pain Society. Published by Elsevier Inc. All rights reserved.
    Journal of Pain 11/2014; 16(2). DOI:10.1016/j.jpain.2014.10.011 · 4.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Urine drug tests (UDTs) are recommended for patients on chronic opioid therapy (COT). Knowledge of the risk factors for aberrant UDT results could help optimize their use.
    Journal of General Internal Medicine 09/2014; 29(12). DOI:10.1007/s11606-014-3010-y · 3.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although opioids are frequently prescribed for chronic non-cancer pain (CNCP) among Veterans Health Administration (VHA) patients, little has been reported on national opioid prescribing patterns in the VHA. Our objective was to better characterize the dosing and duration of opioid therapy for CNCP in the VHA. We analyzed national VHA administrative and pharmacy data for fiscal years 2009 to 2011. For individuals with CNCP diagnoses and any opioid use in the fiscal year, we calculated the distribution of individual mean daily opioid dose, individual total days covered with opioids in a year, and individual total opioid dose in a year. We also investigated the factors associated with being in the top 5% of individuals for total opioid dose in a year, which we term receipt of high volume opioids. About half of the patients with CNCP received opioids in a given fiscal year. The median daily dose was 21 milligrams morphine equivalents. Approximately 4.5% had a mean daily dose higher than 120 milligram morphine equivalents. The median days covered in a year was 115 to 120 days in these years for those receiving opioids. Fifty-seven percent had at least 90 days covered with opioids per year. Major depression and post-traumatic stress disorder were positively associated with receiving high volume opioids, but non-opioid substance use disorders were not. Among VHA patients with CNCP, chronic opioid therapy occurs frequently, but for the large majority of patients the average daily dose is modest. Doses and duration of therapy were unchanged 2009-2011.
    Pain 08/2014; 155(11). DOI:10.1016/j.pain.2014.08.033 · 5.84 Impact Factor

Full-text (2 Sources)

Available from
May 16, 2014